CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM010474
Első szerző:Gombos Tímea
Cím:Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure / Gombos, T., Makó, V., Cervenak, L., Papassotiriou, J., Kunde, J., Hársfalvi, J., Förhécz, Z., Pozsonyi, Z., Borgulya, G., Jánoskuti, L., Prohászka, Z.
Dátum:2009
ISSN:0340-6245 (Print)
Megjegyzések:Decreased activity of ADAMTS13, the von Willebrand factor (VWF) cleaving protease, was recently reported in cardiovascular diseases and in hepatic failure. Chronic heart failure (CHF) is characterised by abnormalities of left ventricular function accompanied by the failure of the liver and dysregulation of endothelial activation. Therefore, the aim of our study was to measure ADAMTS13 activity in CHF, and determine the prognostic value of VWF and ADAMTS13 on major clinical events in CHF. ADAMTS13 activity (measured by FRETS-VWF73 substrate) was decreased in CHF (n = 152, left ventricular ejection fraction <45%), and it correlated negatively with B-type natriuretic peptide (BNP) NYHA (New York Heart Association) classes, markers of synthetic capacity of the liver and endothelial dysfunction (all p<0.005). Both, high VWF:Ag levels (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.189-1.943), and low ADAMTS13/VWF:Ag ratios (HR 0.70, 95% CI 0.58-0.84) independently and significantly predicted short-term (1 year follow-up) clinical adverse events in heart failure (HF). Decreased activity of ADAMTS13 with concomitant high VWF:Ag levels is a significant independent predictor of clinical events in CHF. The levels of the two molecules may integrate the impaired synthetic capacity of the liver and the disturbed endothelial regulation and can therefore be a useful tool to predict clinical events in CHF.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
ADAMTS13
Endothelial dysfunction
Heart failure
Hepatic failure
Von Willebrand factor
brain natriuretic peptide
von Willebrand factor
von Willebrand factor cleaving proteinase
aged
article
clinical assessment
controlled study
disease association
disease severity
endothelial dysfunction
enzyme activity
female
follow up
heart failure
heart left ventricle ejection fraction
human
liver dysfunction
major clinical study
male
priority journal
prognosis
Megjelenés:Thrombosis and Haemostasis. - 102 : 3 (2009), p. 573-580. -
További szerzők:Makó Veronika Cervenak László Papassotiriou, Jana Kunde, Jan Hársfalvi Jolán (1949-) (klinikai biokémikus) Förhécz Zsolt Pozsonyi Zoltán Borgulya Gábor Jánoskuti Lívia Prohászka Zoltán
Internet cím:elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM010447
Első szerző:Molvarec Attila (szülész-nőgyógyász)
Cím:Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAHTS13) activity in preeclampsia / Molvarec, A., Rigó, J., Jr., Bőze, T., Derzsy, Z., Cervenak, L., Makó, V., Gombos, T., Udvardy, M.L., Hársfalvi, J., Prohászka, Z.
Dátum:2009
ISSN:0340-6245 (Print)
Megjegyzések:The activity of ADAMTS13, the von WiIIebrand factor (VWF) cleaving protease is low in several conditions, including HELLP (haemolysis, elevated liver enzymes, and low platelet count) syndrome. As HELLP syndrome develops in most cases on the basis of preeclampsia, our aim was to determine whether plasma ADAMTS13 activity is decreased in preeclampsia. Sixty-seven preeclamptic patients, 70 healthy pregnant women and 59 healthy non-pregnant women were involved in this case-control study. Plasma ADAMTS13 activity was determined with the FRETS-VWF73 assay, while VWF antigen (VWF:Ag) levels with an enzyme-linked immunosorbent assay. The multimeric pattern of VWF was analyzed by SDS-agarose gel electrophoresis. There was no significant difference in plasma ADAMTS13 activity between the preeclamptic and the healthy pregnant and nonpregnant groups (median [25-75 percentile]: 98.8 [76.5-112.8] %, 96.3 [85.6-116.2] % and 91.6 [78.5-104.4] %, respectively; p>0.05). However, plasma VWF:Ag levels were significantly higher in preeclamptic patients than in healthy pregnant and non-pregnant women (187.1 [145.6-243.1] % versus 129.3 [105.1-182.8] % and 70.0 [60.2-87.3] %, respectively; p<0.001). The multimeric pattern of VWF was normal in each group. Primiparas had lower plasma ADAMTS13 activity than multiparas (92.6 [75.8-110.6] % versus 104.2 [92.1-120.8] %; p=0.011). No other relationship was found between clinical characteristics, laboratory parameters and plasma ADAMTS13 activity in either study group. In conclusion, plasma ADAMTS13 activity is normal in preeclampsia despite the increasedVWF:Ag levels. However, further studies are needed to determine whether a decrease in plasma ADAMTS13 activity could predispose preeclamptic patients to develop HELLP syndrome.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
ADAMTS13
HELLP syndrome
Preeclampsia
Pregnancy
Von Willebrand factor
von Willebrand factor
von Willebrand factor cleaving proteinase
ADAM protein
ADAMTS13 protein
human
biological marker
adult
agar gel electrophoresis
article
case control study
controlled study
enzyme linked immunosorbent assay
female
HELLP syndrome
hemolysis
human
laboratory test
liver
major clinical study
preeclampsia
priority journal
protein blood level
thrombocyte count
blood
enzymology
parity
pregnancy
protein multimerization
upregulation
ADAM Proteins
Adult
Biological Markers
Case-Control Studies
Female
HELLP Syndrome
Humans
Parity
Pre-Eclampsia
Pregnancy
Protein Multimerization
Up-Regulation
von Willebrand Factor
Young Adult
Megjelenés:Thrombosis and Haemostasis. - 101 : 2 (2009), p. 305-311. -
További szerzők:Rigó János (1958-) (szülész-nőgyógyász) Bőze Tamás Derzsy Zoltán Cervenak László Makó Veronika Gombos Tímea Udvardy Miklós László (1977-) (orvos, tudományos segédmunkatárs) Hársfalvi Jolán (1949-) (klinikai biokémikus) Prohászka Zoltán
Internet cím:elektronikus változat
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1